Corcept Therapeutics (CORT) – Hot Guidance
-
Corcept Therapeutics (CORT) Tops Q3 EPS by 4c, Revenues Miss; Narrows FY20 Revenue Guidance Below Consensus
-
Corcept Therapeutics (CORT) Tops Q1 EPS by 12c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
Back to CORT Stock Lookup